Moody's Boosts Outlook on Celgene (CELG) to Stable; Affirms Ratings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Celgene (CELG) Adds $3B to Buyback Plan
June 12, 2013 8:01 AM EDTCelgene Corp (NASDAQ: CELG) announced today that its Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Companys common stock. Purchases may be made in the open market or in privately negotiated transactions from time to time, as... More
Celgene (CELG) Unit Reports Meaningful Improvements Observed in PALACE 1
June 12, 2013 7:35 AM EDTCelgene International SÃ rl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced 52-week results from PALACE 1, the Companys first phase III study in psoriatic arthritis at the European Congress of Rheumatology (EULAR) annual meeting in Madrid, Spain. The results were included in the EULAR press conference, which highlights data considered representative of highest quality and most meaningful research presented at EULAR. The full PALACE 1 oral presentation will be presented later today.
Long-term results presented from PALACE 1 revealed meaningful improvements in American College of Rheumatology (ACR) 20 scores from week 24 through week 52. Patients who... More
